ALNY – Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.ALNY
$459.58Name : Alnylam Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $60,241,293,312.00
EPSttm : -2.49
Alnylam Pharmaceuticals, Inc.
$459.58
1.68%$7.58Float Short %
2.96
Margin Of Safety %
Put/Call OI Ratio
1.19
EPS Next Q Diff
2.74
EPS Last/This Y
6.18
EPS This/Next Y
5.95
Price
459.58
Target Price
474.04
Analyst Recom
1.7
Performance Q
43.23
Relative Volume
0.69
Beta
0.3
Ticker: ALNY
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | ALNY | 455.02 | 1.21 | 1.74 | 19501 |
| 2025-09-09 | ALNY | 482.79 | 1.22 | 0.70 | 19848 |
| 2025-09-10 | ALNY | 469.12 | 1.20 | 1.34 | 20516 |
| 2025-09-11 | ALNY | 468.5 | 1.21 | 0.74 | 21098 |
| 2025-09-12 | ALNY | 465.77 | 1.21 | 0.70 | 21140 |
| 2025-09-15 | ALNY | 461.19 | 1.20 | 1.04 | 21354 |
| 2025-09-16 | ALNY | 460.99 | 1.21 | 0.05 | 21533 |
| 2025-09-17 | ALNY | 451.73 | 1.1947854316729 | 0.68098159509202 | 21634 |
| 2025-09-18 | ALNY | 451.77 | 1.20 | 1.38 | 21618 |
| 2025-09-22 | ALNY | 458.66 | 0.95 | 9.30 | 13304 |
| 2025-09-23 | ALNY | 454.41 | 1.04 | 1.94 | 13960 |
| 2025-09-24 | ALNY | 458.49 | 1.16 | 0.09 | 17007 |
| 2025-09-25 | ALNY | 449.22 | 1.15 | 1.36 | 17121 |
| 2025-09-26 | ALNY | 446.22 | 1.16 | 0.38 | 17546 |
| 2025-09-29 | ALNY | 447.37 | 1.15 | 1.11 | 17579 |
| 2025-09-30 | ALNY | 455.78 | 1.17 | 1.50 | 17814 |
| 2025-10-01 | ALNY | 460.66 | 1.18 | 0.26 | 18302 |
| 2025-10-02 | ALNY | 461.12 | 1.18 | 1.80 | 18426 |
| 2025-10-03 | ALNY | 455.91 | 1.19 | 2.89 | 18653 |
| 2025-10-06 | ALNY | 451.81 | 1.21 | 1.06 | 18865 |
| 2025-10-07 | ALNY | 459.65 | 1.19 | 1.32 | 19169 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | ALNY | 455.03 | 386.6 | 1027.3 | 3.92 |
| 2025-09-09 | ALNY | 482.42 | 377.9 | 1070.9 | 3.74 |
| 2025-09-10 | ALNY | 469.21 | 377.9 | 1000.0 | 3.74 |
| 2025-09-11 | ALNY | 468.58 | 377.9 | 1020.6 | 3.74 |
| 2025-09-12 | ALNY | 465.73 | 377.9 | 1016.9 | 3.74 |
| 2025-09-15 | ALNY | 461.24 | 377.9 | 1013.7 | 3.78 |
| 2025-09-16 | ALNY | 461.24 | 377.9 | 1022.0 | 3.78 |
| 2025-09-17 | ALNY | 451.23 | 377.9 | 1004.1 | 3.78 |
| 2025-09-18 | ALNY | 452.02 | 388.2 | 1022.4 | 3.86 |
| 2025-09-19 | ALNY | 453.72 | 388.2 | 1024.6 | 3.86 |
| 2025-09-22 | ALNY | 458.92 | 388.2 | 1031.5 | 3.86 |
| 2025-09-23 | ALNY | 454.44 | 388.2 | 1013.9 | 3.86 |
| 2025-09-24 | ALNY | 458.78 | 388.2 | 1029.7 | 3.86 |
| 2025-09-25 | ALNY | 449.58 | 388.2 | 1006.2 | 3.86 |
| 2025-09-26 | ALNY | 446.40 | 388.2 | 1016.1 | 3.86 |
| 2025-09-29 | ALNY | 447.49 | 393.3 | 1023.8 | 3.94 |
| 2025-09-30 | ALNY | 455.71 | 393.3 | 1036.8 | 3.94 |
| 2025-10-01 | ALNY | 460.86 | 393.3 | 1030.5 | 3.94 |
| 2025-10-02 | ALNY | 461.23 | 393.3 | 1022.9 | 3.94 |
| 2025-10-03 | ALNY | 456.10 | 393.3 | 1013.2 | 3.94 |
| 2025-10-06 | ALNY | 451.95 | 393.3 | 1005.8 | 3.94 |
| 2025-10-07 | ALNY | 459.58 | 419.8 | 1035.5 | 4.00 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | ALNY | -2.47 | 2.04 | 2.73 |
| 2025-09-09 | ALNY | -2.47 | 2.04 | 2.73 |
| 2025-09-10 | ALNY | -2.47 | 2.04 | 2.73 |
| 2025-09-11 | ALNY | -2.77 | 2.04 | 3.17 |
| 2025-09-12 | ALNY | -2.77 | 2.04 | 3.17 |
| 2025-09-15 | ALNY | -2.77 | 2.04 | 3.17 |
| 2025-09-16 | ALNY | -2.77 | 2.04 | 3.17 |
| 2025-09-17 | ALNY | -2.77 | 2.04 | 3.17 |
| 2025-09-18 | ALNY | -2.77 | 2.04 | 3.17 |
| 2025-09-19 | ALNY | -2.77 | 2.04 | 3.17 |
| 2025-09-22 | ALNY | -2.77 | 2.04 | 3.17 |
| 2025-09-23 | ALNY | -2.77 | 2.04 | 3.17 |
| 2025-09-24 | ALNY | -2.77 | 2.04 | 3.17 |
| 2025-09-25 | ALNY | -2.77 | 2.04 | 2.96 |
| 2025-09-26 | ALNY | -2.48 | 2.04 | 2.96 |
| 2025-09-29 | ALNY | -2.48 | 2.06 | 2.96 |
| 2025-09-30 | ALNY | -2.48 | 2.06 | 2.96 |
| 2025-10-01 | ALNY | -2.48 | 2.06 | 2.96 |
| 2025-10-02 | ALNY | -2.48 | 2.06 | 2.96 |
| 2025-10-03 | ALNY | -2.48 | 2.06 | 2.96 |
| 2025-10-06 | ALNY | -2.86 | 1.99 | 2.96 |
| 2025-10-07 | ALNY | -2.86 | 1.99 | 2.96 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.51
Avg. EPS Est. Current Quarter
1.47
Avg. EPS Est. Next Quarter
2.23
Insider Transactions
-2.86
Institutional Transactions
1.99
Beta
0.3
Average Sales Estimate Current Quarter
943
Average Sales Estimate Next Quarter
1195
Fair Value
Quality Score
41
Growth Score
53
Sentiment Score
75
Actual DrawDown %
5.1
Max Drawdown 5-Year %
-42.5
Target Price
474.04
P/E
Forward P/E
75.25
PEG
P/S
24.47
P/B
240.21
P/Free Cash Flow
EPS
-2.47
Average EPS Est. Cur. Y
4
EPS Next Y. (Est.)
9.95
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-12.96
Relative Volume
0.69
Return on Equity vs Sector %
-152.5
Return on Equity vs Industry %
-138.8
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.26
EBIT Estimation
1035.5
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2230
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading